Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Net Income (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Net Income data on record, last reported at -$2.0 million in Q4 2025.

  • For Q4 2025, Net Income rose 21.23% year-over-year to -$2.0 million; the TTM value through Dec 2025 reached -$7.7 million, up 3.06%, while the annual FY2025 figure was -$8.2 million, 6.34% down from the prior year.
  • Net Income reached -$2.0 million in Q4 2025 per INM's latest filing, down from -$1.7 million in the prior quarter.
  • Across five years, Net Income topped out at -$336591.0 in Q2 2023 and bottomed at -$7.9 million in Q2 2022.
  • Average Net Income over 5 years is -$2.6 million, with a median of -$2.1 million recorded in 2022.
  • Peak YoY movement for Net Income: skyrocketed 95.72% in 2023, then crashed 473.57% in 2024.
  • A 5-year view of Net Income shows it stood at -$4.3 million in 2021, then surged by 51.01% to -$2.1 million in 2022, then rose by 29.55% to -$1.5 million in 2023, then plummeted by 74.2% to -$2.6 million in 2024, then rose by 21.23% to -$2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$2.0 million in Q4 2025, -$1.7 million in Q3 2025, and -$1.8 million in Q2 2025.